Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study
Conclusions
Humoral response after COVID-19 was lower in patients with MS with fingolimod or anti-CD20 mAb. These patients could therefore be at risk of recurrent infection and could benefit from anti–SARS-CoV-2 vaccination. The humoral response after vaccination and the delay before vaccination need to be evaluated.
Classification of Evidence
This study provides Class IV evidence that patients treated with fingolimod or anti-CD20 monoclonal antibodies for MS have a lower humoral response after COVID-19 compared with patients without DMTs or with another DMTs.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Bigaut, K., Kremer, L., Fabacher, T., Lanotte, L., Fleury, M.-C., Collongues, N., de Seze, J. Tags: COVID-19, Multiple sclerosis Article Source Type: research
More News: Avonex | Brain | Coronavirus | COVID-19 | Gilenya | Multiple Sclerosis | Neurology | Rebif | Respiratory Medicine | SARS | Study | Vaccines